Defence Therapeutics Receives USPTO Allowance for Patent Application Covering Next-Gen ADC Technology
- Patent protection until 2043 provides long-term market exclusivity for ADC technology
- Enhanced preclinical performance compared to conventional ADCs in cancer models
- Broad patent coverage including composition-of-matter claims and therapeutic applications
- Expanding patent portfolio across multiple jurisdictions strengthens IP position
- Technology still in preclinical stage, requiring significant development before commercialization
- Pending patent applications in key markets like Canada and Europe create uncertainty
Montreal, Quebec--(Newsfile Corp. - June 9, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specializing in drug delivery technologies, is pleased to announce that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for its U.S. patent application covering one of its next-generation antibody-drug conjugate (ADC) technologies. The allowance of U.S. patent application no. 18/351,291 ('291) includes valuable composition-of-matter claims broadly covering therapeutically active ADCs - not limited to individual diseases or therapeutic targets - as well as claims covering the use of ADCs for treating or diagnosing diseases such as cancer.
Defence's Accum®-based ADCs have demonstrated enhanced intracellular delivery and cytotoxic activity in multiple preclinical cancer models compared to conventional ADCs. Upon grant, the '291 patent application will provide the Company with potential market exclusivity until 2043 for its proprietary second-generation Accum®-based ADCs, which include antibodies conjugated to innovative new constructs featuring a bile acid conjugated to a nuclear localization signal (NLS) derived from the ribosomal protein eS17 (RPS17).
This milestone builds on Defence's established patent portfolio for its foundational Accum® technology, which includes granted patents in the United States (US 11,352,437), Japan (JP 7,126,956), Australia (AU 2017233725), and Israel (IL 261765), with applications currently pending in Canada and Europe.
"Second-generation Accum®-based ADCs represent a significant advancement in both oncotherapy and targeted drug delivery," said Sébastien Plouffe, CEO and Founder of Defence Therapeutics. "This recent allowance underscores the innovation and versatility embedded in our ADC platform technology and reflects our commitment to developing novel, effective cancer treatments that push the boundaries of current ADC technologies."
This newly allowed U.S. patent application is poised to become the eighth granted U.S. patent in Defence's expanding portfolio, which now comprises seven published patent families.
About Defence:
Defence Therapeutics is a publicly-traded clinical-stage biotechnology company developing and engineering the next generation of ADC products using its proprietary platform. The core of Defence Therapeutics platform is the ACCUM® technology, which enables precision delivery of ADCs in their intact form to target cells. As a result, increased efficacy and potency can be reached against cancer.
For further information:
Sebastien Plouffe, President, CEO and Director
P: (514) 947-2272
Splouffe@defencetherapeutics.com
www.defencetherapeutics.com
Cautionary Statement Regarding "Forward-Looking" Information
This release includes certain statements that may be deemed "forward-looking statements". All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.
Neither the CSE nor its market regulator, as that term is defined in the policies of the CSE, accepts responsibility for the adequacy or accuracy of this release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/254853
FAQ
What is the significance of Defence Therapeutics' (DTCFF) new patent allowance?
How does Defence Therapeutics' Accum-based ADC technology perform compared to conventional ADCs?
What is the current patent portfolio status of Defence Therapeutics (DTCFF)?
What unique features does Defence Therapeutics' new ADC technology include?
When will Defence Therapeutics' (DTCFF) new ADC patent expire?
